https://www.live-feeds.com/feed/novartis-s-latest-trial-setback-sinks-stockContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novartis-s-latest-trial-setback-sinks-stockhttps://www.live-feeds.com/feed/novartis-s-latest-trial-setback-sinks-stock#u62349Wed, 09 Sep 2026 05:10:40 +0000Novartis shares dropped between 10% and 14% after the Phase III HARBOR study for delpacibart etedesiran failed to show statistically significant improvement in patients with myotonic dystrophy type 1. This failure marks the second pipeline setback for the company this week and the third drug trial setback overall. The drug was a centerpiece of a 12 billion dollar Avidity buyout. The failure also impacted Amgen, whose stock fell 10% as the result cast doubt on the entire Lp(a) cholesterol drug class.Why it mattersThe HARBOR study targeted a specific genetic muscle wasting disease. Novartis had